Monitor for any subsequent grants under the expanded equity plan and for the Board's decision on the reverse stock split ratio, which could affect share price and liquidity. No immediate trading catalyst.
Price Chart
Executive Summary
OneMedNet Corp filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on September 18, 2026. Stockholders approved an amendment to the 2022 Equity Incentive Plan to increase the authorized share reserve by 1,000,000 shares, elected three Class III directors, ratified the appointment of WithumSmith+Brown, PC as independent auditor, and approved a reverse stock split authorization at a ratio between 1-for-5 and 1-for-20. This is a routine governance filing with no financial results or material operational changes.
Key Facts
- Stockholders approved an amendment to the 2022 Equity Incentive Plan to increase the available share reserve by 1,000,000 shares (34,528,269 votes for, 1,868,479 against).
- Three Class III directors were elected: Dr. Kenneth Alleyne, Sherry Coonse McCraw, and Dr. Jeffrey Yu, each to serve three-year terms expiring at the 2029 Annual Meeting.
- Ratification of WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026 was approved (41,660,426 votes for, 138,717 against).
- Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-20, as determined by the Board (41,068,200 votes for, 739,329 against).
- The 2022 Equity Incentive Plan was amended and restated effective September 18, 2026, authorizing an aggregate of 3,357,223 Common Shares with an automatic annual increase of up to 1,000,000 shares.
Financial Impact
No financial impact disclosed. The equity incentive plan amendment increases share reserve by 1,000,000 shares, but no grants were reported.
Risk Factors
- Potential dilution from future equity awards under the expanded plan.
- Reverse stock split authorization could signal management's concern about maintaining Nasdaq listing compliance.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043943 |
| Document: form8-k.htm | 0001493152-26-043943 |
| Document: 0001493152-26-043943-index-headers.html | 0001493152-26-043943 |
| Document: 0001493152-26-043943-index.html | 0001493152-26-043943 |
| Document: 0001493152-26-043943.txt | 0001493152-26-043943 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $0.0295 | awaiting T+60 | — | — |
Apr 20, 2026 27w ago | 8-K | $0.0740 $0.0341 | ▲ +53.92% | ▲ +60.82% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers